Objective: To evaluate preoperative total testosterone (TT) as a predictor of positive surgical margins (PSM) in prostate cancer (PCA). Patients and methods: During the period from November 2014 to July 2017, preoperative TT was measured in 476 PCA patients undergoing only radical prostatectomy (RP) and including all risk classes. Surgical margins were stated negative, focal positive (single and less than 1 mL), and multifocal positive (more than 1). The risk of TT and clinical factors associated with the risk of PSM (focal or multifocal versus negative) was evaluated by the multinomial logistic regression model. Results: Overall, PSM were detected in 149 cases (31.3%), which included 99 patients with focal cancer invasion (20.8%) and 50 subjects with multifocal cancer invasion (10.5%). In univariate analysis, PSM associated with higher median levels of TT and prostate-specific antigen than controls. Multifocal PSM associated with higher rates of high-risk PCA (42%) than focal (22.2%) or control cases (18.3%). In multivariate analysis, TT was the only independent factor positively associated with the risk of focal PSM when compared to controls (OR 1.002; p = 0.035). TT (OR 1.003; p = 0.002) and high-risk PCA (OR 1.002; p = 0.047) were independent factors, which positively associated with the risk of multifocal PSM when compared to controls. Risk models were computed. Conclusions: In a large and contemporary cohort of patients elected to primary RP, TT was an -independent positive factor associated with the risk of focal and multifocal PSM. TT associated with aggressive PCA biology.

Keywords:
Prostate cancer, Radical prostatectomy, Total testosterone, Surgical margins, Prostatic chronic inflammation, Prostate cancer tumor grade, Prostate-specific antigen, Prostate biopsy
1.
Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 2002; 168: 9–12.
2.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.
3.
Klap J, Schmid M, Loughlin R: The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 2015; 193: 403–414.
4.
Lopez DS, Advani S, Tsilidis KK, Wang R, Canfield S: Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk? Transl Androl Urol 2017; 6: 566–579.
5.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280: 969–974.
6.
Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewcz PI, Montironi R, Montorsi F: Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009; 55: 87–99.
7.
Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S: Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int 2018; 100: 251–262.
8.
Menon M, Tewari A, Peabody J: Vattikuti Institute prostatectomy: technique. J Urol 2003; 169: 2289–2292.
9.
Walsh PC, Retik AB, Vaughan ED: Anatomic radical retropubic prostatectomy; in Campbell's Urology (ed 8). Philadelphia, Elsevier, 2002, vol 4, chapter 90, pp 3107–3129.
10.
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F: Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012 61: 480–487.
11.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI: Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013; 111: 753–760;
12.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA: A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016; 69: 428–435.
13.
Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM: Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009; 133: 1568–1576.
14.
Alchin D, Murphy D, Lawrentschuk N: Predicting the risk of positive surgical margins following robotic-assisted radical prostatectomy. Minerva Urol Nefrol 2017; 69: 56–62.
15.
Herlemann A, Cowan J, Carrol PR, Cooperberg MR: Community-based outcomes of open versus robot-assisted radical prostatectomy. Eur Urol 2018; 73: 215–223.
16.
Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Dunglison N, Carter R, Williams S, Payton DJ, Perry-Keene J, Lavin MF, Gardiner RA: Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016; 388: 1057–1066.
17.
Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM: Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178–2180;
18.
Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, Takeshita H, Ishikawa Y, Fukui I: Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696–701.
19.
Kwon T, Jeong IG, You D, Park MC, Hong JH, Ahn H, Kim CS: Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level? BJU Int 2010; 106: 633–638.
20.
Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud JP: Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patients. Horm Mol Biol Clin Investig 2010; 2: 191–201
21.
Dai B, Qu Y, Kong Y, Ye D, Yao X, Zhang S, Wang C, Zhang H, Yang W: Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8–10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int 2012; 110(11 pt B): E667–E672.
22.
Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A: Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int 2011; 107: 1400–1403.
23.
Salonia A, Gallina A, Abdollah F, Briganti A, Capitanio U, Suardi N, Ferrari M, Raber M, Colombo R, Freschi M, Rigatti P, Montorsi F: Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. World J Urol 2012; 30: 533–539.
24.
Cabral PH, Iwamoto MW, Fanni VS, Barros Lda R, Cardoso SN, Mello LF, Glina S: Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer. Int Braz J Urol 2013; 39: 173–181
25.
Jentzmik F, Schnoeller TJ, Cronauer MV, Steinestel J, Steffens S, Zengerling F, Al Ghazal A, Schrader MG, Steinestel K, Schrader AJ: Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage. Int J Urol 2014; 21: 980–986.
26.
Llukani E, Katz BF, Agalliu I, Lightfoot A, Yu SS, Kathrins M, Lee Z, Su YK, Monahan Agnew K, McGill A, Eun DD, Lee DI: Low levels of serum testosterone in middle-aged men impact pathological features of prostate cancer. Prostate Int 2017; 5: 17–23.
27.
Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdonà S, Autorino R, Cantiello F, La Rocca R, Busetto GM, Cimmino A, Buonerba C, Battaglia M, Damiano R, De Cobelli O, Mirone V, Terracciano D. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget 2017; 8: 18424–18434.
28.
Yoo S, You D, Kim YS, Hong JH, Ahn H, Kim CS: Combination of androgen deprivation therapy and salvage radiotherapy versus salvage radiotherapy alone for recurrent prostate cancer after radical prostatectomy. Urol Int 2017; 99: 406–413.
29.
Fahmy O, Khairul-Asri MG, Hadi SHSM, Gakis G, Stenzl A: The role of radical prostatectomy and radiotherapy in treatment of locally advanced prostate cancer: a systematic review and meta-analysis. Urol Int 2017; 99: 249–256.
30.
Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F: Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res 2012; 18: 3648–3657.
31.
Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500–507.
32.
Porcaro AB, De Luyk N, Corsi P, Sebben M, Tafuri A, Processali T, Cerasuolo M, Mattevi D, Cerruto MA, Brunelli M, Siracusano S, Artibani W: Association between basal total testosterone levels and tumor upgrading in low and intermediate risk prostate cancer. Urol Int 2017; 99: 215–221.
33.
Porcaro AB, Cavicchioli F, De Luyk N, Mattevi D, Corsi P, Sebben M, Tafuri A, Processali T, Inverardi D, Cacciamani G, De Marchi D, Balzarro M, Cerruto MA, Brunelli M, Novella G, Siracusano S, Artibani W: Clinical factors predicting tumour upgrading in patients under active surveillance and elected to active treatment after disease reclassification or progression. Urol Int 2017; 99: 186–193.
34.
Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, Arredouani MS: Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci U S A 2014; 111: 9887–9892.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.